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ngendijk@umThe favorable beamproperties of protons can be translated into clinical beneﬁts by target dose
escalation to improve local control without enhancing unacceptable radiation toxicity or to
spare normal tissues to prevent radiation-induced side effectswithout jeopardizing local tumor
control. For the clinical validation of the added value of protons to improve local control,
randomized controlled trials are required. For the clinical validation of the added value of
protons to prevent side effects, both model-based validation or randomized controlled trials
can be used. Model-based patient selection for proton therapy is crucial, independent of the
validation approach. Combining these approaches in rapid learning health care systems is
expected to yield the most efﬁcient and scientiﬁcally sound way to continuously improve
patient selection and the therapeuticwindow, eventually leading tomore cancer survivorswith
better quality of life.
Semin Radiat Oncol 28:79-87C 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
There is a widespread and ongoing discussion on thepresumed lack of evidence of protons over photons,
which is the most frequently used radiation technique and
currently still considered the reference standard for most/j.semradonc.2017.11.008
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cg.nlindications.1-5 The term “lack of evidence” is often used when
results from randomized controlled trials (RCTs) comparing a
new treatment modality (eg, protons) with the current stand-
ard (eg, photons) is lacking. In this respect, it is important to
note that new radiation techniques have rarely been introduced
in clinical practice based on the results of RCTs.6
Most new radiation techniques are clinically introduced
because they allow for better dose conformity (eg, intensity
modulated radiotherapy [IMRT], volumetric modulated arc
therapy or RapidArc, and protons) and thus better sparing of
normal tissues without jeopardizing target dose coverage. To
justify the introduction of such techniques in clinical practice,
radiation oncologists generally refer to the “ALARA principle,”
ie, the principle of radioprotection stating that whenever
ionizing radiation is applied in humans, animals, or materials,
exposure should be “as low as reasonably achievable.”7 As
compared to diagnostic imaging, the ALARA principle is
considered even more relevant in radiotherapy as the levels
of dose exposure administered are markedly higher and more
likely to result in clinically apparent acute and late side effects
and secondary tumor induction. However, the question arises
to what extent themuch higher capital and operational costs of
proton therapy compared to photon therapy translate into
clinically relevant reductions of radiation-induced side effects.79
rticle under the CC BY-NC-ND license
J.A. Langendijk et al.80In view of the rising costs of health care, there is a growing
societal demand that before the introduction of a new
technology in health care such as proton therapy, it must have
been shown to be cost-effective, instead of simply referring to
the ALARA principle.
On the other side of the spectrum, there are those who
propose a direct comparison of protons and photons using the
classical approach of an RCT as the one and only acceptable
standard of evidence-based medicine, like that used for drug
approval. However, there is a growing awareness among
different stakeholders that evaluating new technologies with
the assessment paradigm used for drug approval may not be
the most optimal approach either.8 RCTs for comparing
radiation technologies are much more challenging than for
pharmaceutical drugs, owing to the interplay between tech-
nological complexity, user skills, local workﬂows (eg, range
and dose veriﬁcation procedures), additional equipment (eg,
treatment planning systems), and learning curve issues, which
may all inﬂuence the beneﬁts and risks for protons and confuse
standardization of the treatment arms. In addition, owing to
rapid technological developments in proton therapy, there is a
continuous threat that at the time the results of RCTs become
available, the outcome will be based on outdated technology
and thus not be considered valuable and practice changing.
This is not uncommon and has been seen for example for
IMRT in head and neck cancer, where results from RCTs that
compared IMRT vs 3-dimensional conformal radiotherapy
became available when IMRT was already widely used in
routine clinical practice.6 Recently, The Royal Netherlands
Academy of Arts and Sciences (KNAW) produced a Foresight
Report on the Evaluation of New Technology in Health Care,
providing guidelines for research suitable for assessing and
inferring the beneﬁts and performance of new technology in
health care.8 They concluded that an RCT is not always the
most optimal study design for evaluating the beneﬁt of
technology, that a one-size-ﬁts-all approach for the evaluation
of medical devices is impossible and that for different types of
new applications, different research approaches are required.
In this paper, alternative approaches for an evidence-based
sustainable clinical introduction of proton therapy are dis-
cussed in addition to methodological problems of RCTs for
comparing protons with photons, especially in relation to the
eventual introduction of protons into routine clinical practice.Clinical Applications of Proton
Therapy
The favorable beam properties of protons over photons can be
translated into clinical beneﬁts in roughly 2 ways.
First, protons can be applied to escalate the dose to the target
to improve local tumor control and subsequent overall survival
without enhancing additional or unacceptable side effects.
According to the Dutch Health Council, dose escalation is the
expected future indication for proton therapy in approximately
15% of the cases. This strategy, primarily aiming at improving
outcome in terms of efﬁcacy requires the classical approach of
an RCT as neither the beneﬁt in terms of improvement of localcontrol and overall survival are known, nor the risks of
increasing the dose beyond levels that are normally given to
normal tissues in or nearby the target.
Second, protons can be applied to decrease the dose to
normal tissues with an equivalent target dose, primarily aiming
to prevent acute and late radiation-induced side effects or
secondary tumor induction while maintaining similar local
tumor control. In the Netherlands, this is the expected
application in 85% of the future patients. For this application,
clinical validation can be obtained through RCTs under certain
speciﬁc conditions, but for this strategy alternative method-
ologies, like the so-called model-based approach, can be
considered as well.1,2The Model-Based Approach
The model-based approach is based on the principle that the
risk of radiation-induced side effects can be reliably predicted
by multivariable normal tissue complication probability
(NTCP) models, which are prediction models describing the
relationship between dose-volume parameters and the risk on
a given side effects.1 Multivariable NTCP-models consist of at
least 1 or more dose-volume parameters either or not in
combination with other independent predictors (eg, the
addition of concurrent chemotherapy or age).9-11 The
model-based approach can be used to select patients for
protons (model-based selection); in addition, for the model-
based approach it is also essential to continuously and
prospectively validate the clinical models for protons (model-
based validation).Model-Based Selection
In model-based selection we distinguish 3 steps.
The ﬁrst step in the model-based approach is to select an
NTCP-model or a set of NTCP-models from literature, for
acute and late radiation-induced side effects that are considered
most relevant (Fig. 1).
In the second step, the dose-volume parameters of the
selected NTCP-models are used for optimization of radio-
therapy treatment plans, either based on photons or protons
(model-based optimization). As prevention of radiation-
induced side effects can only be expected when the relevant
dose metrics with protons are lower than with photons, the
differences between the best proton plan and the best photon
plan (Δdose) with respect to the dose-volume parameters in
the NTCP-models is assessed by performing a planning
comparison study in every single patient.
Step 3 determines to what extent Δdose translates into a
difference in complication probability (ΔNTCP) by integrating
the results of the planning comparative study into NTCP-
models. This ﬁnal step is necessary as not every Δdose will
translate into a clinically relevant ΔNTCP, for example,
because the dose with photons already remains under a
predeﬁned threshold for a given complication or because of
a relatively ﬂat dose-response relationship in the respective
Δdose area.
Step 3: Translate ∆Dose into ∆NTCPStep 2: Planning comparison
∆Dose



































VMAT (photons): D = 60 Gy
IMPT (protons): D = 45 Gy
Figure 1 Graphical display of the model-based selection procedure. The ﬁrst step includes selection of an NTCP-model.
Based on the dose-volume parameters included in the selected NTCP-model, the dose distribution is optimized for both
techniques (model-based plan optimization) andΔdose is assessed (step 2). Finally, the outcome of step 2 is integrated in
the NTCP-model to translate Δdose into ΔNTCP (step 3). (Color version of ﬁgure is available online.)
Clinical trial strategies 81As such, model-based selection is a tool to select patients for
proton therapy that are expected to beneﬁt most from this new
technology and is a good example of personalizedmedicine. In
addition, a recent study in head and neck cancer patients
showed that model-based selection is more likely to be
cost-effective than treating all patients with either IMRT or
protons.12 To guarantee uniform decision making, the Dutch
Society of Radiation Oncology deﬁned the thresholds for
ΔNTCP, which depend on the grading according to the
Common Toxicity of Adverse Events version 4.1
(CTCAEv4.0). There is consensus that grade 1 toxicity is not
relevant for model-based selection, as this only indicates
objective signs of radiation-induced toxicity without any
impact for patients or patients’ function. In case of grade II,
III, and IV-V, the ΔNTCP thresholds that will be used are
≥10%,≥5%, and≥2%, respectively, based on the assumption
that higher grades of toxicity have more impact on daily
function and quality of life.
When multiple NTCP-models for different endpoints
are used, the model-based selection procedure eventually
results in a so-called ΔNTCP-proﬁle that can considered a
biomarker providing quantitative information on the
expected beneﬁt of protons compared to protons
(Fig. 2). For this situation, the Dutch consensus deﬁned
additional thresholds for model-based selection based on
∑ΔNTCP, for example, when 2 NTCP-models are
selected, the∑ΔNTCP threshold is ≥15% with a minimal
ΔNTCP threshold of ≥5% for each NTCP-model. Metic-
ulous prospective registration of radiation-induced tox-
icities including their treatment is required, to determine
whether these thresholds indeed lead to a cost-effective
indication for proton therapy.NTCP-Model Selection
The next question is which NTCP-models can be used for
model-based selection. The Dutch Platform for Proton Ther-
apy (LPPT) deﬁned the following quality criteria for NTCP-
models:(1) NTCP-models are preferably based on the results of
prospective cohort studies, as retrospective assessment
of radiation-induced toxicities generally results in
underreporting of both the prevalence and the severity
of complications. For certain complications, other study
designs may be appropriate (eg, nested case control
studies), such as complications with very long latency
times like cardiac complications after breast cancer
radiotherapy or secondary tumor induction.13,14(2) The number of patients and events should be sufﬁcient.
In the case ofmultivariable logistic analysis, a general rule
of thumb is that at least 10-15 events are needed for each
candidate variable entered in the multivariable model.(3) NTCP-models preferably aremultivariable, considering
the effect of dose-volume variables next to other
independent predictors to obtain more accurate pre-
dictions of the complications risks.(4) TheNTCP-model is presented such that it is possible to
calculate the NTCP-values for each individual and for
each radiation plan, for example, using an equation, a
nomogram, or a graph;(5) Modern internal validation techniques are applied like
bootstrapping or cross-validation.(6) Information onmodel performance is available in terms
of discrimination and calibration. Discrimination refers
to the ability of a model to distinguish patients that will
Figure 2 Model-based selection based onΔNTCP-proﬁle. In case multiple NTCP-models are selected for different toxicity
endpoints, the model-based selection procedures results in a Δdose-proﬁle, based on the difference between the dose-
volume signatures of photons vs protonswhich is translated into theΔNTCP-proﬁle based on a set ofmultivariableNTCP-
models. TheΔNTCP-proﬁle can be considered a biomarker providing quantitative information on a comprehensive set of
toxicity risks. The intensity of the green color corresponds linearlywithΔNTCP.ΔNTCP-proﬁles can be used as a decision
support system to decide between photons and protons. The Dutch Society for Radiation Oncology deﬁned standard
thresholds forΔNTCP-proﬁles based on toxicity grading according to the Common Toxicity Criteria for Adverse Events.
ΔNTCP-proﬁles can also contain patient-reported outcome measures. (Color version of ﬁgure is available online.)
J.A. Langendijk et al.82or will not develop a given complication, whereas
calibration refers to the agreement between predicted
and observed outcome.(7) The NTCP-model is externally validated in an inde-
pendent data set, preferably in another center. Different
levels of external validation can be distinguished and
may range from an independent cohort dataset from
the same center treated with the same technique
(photons) to a cohort from another center with the
new technique (protons).In theNetherlands, themodel-based selection procedure for
proton therapy has been accepted by the National Health Care
Institute (ZiN), which determines whether new types of health
care should be included in the basic health insurance package.
In 2012 ZiN concluded that the model-based approach can be
considered an appropriate evidence-based method to select
patients for proton therapy. Consequently, when patients are
selected according to the model-based selection procedure,
proton therapy is insured care and will be reimbursed by the
health care insurers.Model-Based Validation
The ﬁnal step in the model-based approach is to clinically
validate if a new radiation technique indeed results in less side
effectswhen the relevant dose-volumeparameters in themodelare decreased by optimizing dose distributions using dose-
volume constraints based on the NTCP-models.1 Recently,
Christianen et al11 were the ﬁrst to validate the NTCP model
for swallowing dysfunction that had been developed in stand-
ard IMRT for head and neck cancer, in patients treated with
swallowing sparing IMRT.
In a prospective model-based validation study to assess the
added value of protons over photons,ΔNTCP is determined in
all patients before inclusion, according to the ﬁrst 3 steps
described in the previous paragraph (Fig. 3). Patients are only
included if they meet the predeﬁned criteria for ΔNTCP.
Eligible patients are treated with themost optimal proton plan,
deﬁned as the plan with the highest ΔNTCP compared to the
best photon plan.
Subsequently, the average NTCP for both photon plans
(NTCPphotons) and proton plans (NTCPprotons) of all included
patients are calculated, which provides information on the
expected toxicity rates with photons and protons and the
average ΔNTCP, respectively. Finally, the observed complica-
tion rate among those that have been selected for proton
therapy is calculated and compared to NTCPphotons, also
referred to as calibration-in-the large.15 The null-hypothesis,
ie, proton therapy does not improve complication rates as
compared to photons, is rejected if the observed complication
rate with protons is signiﬁcantly lower than NTCPphotons. A
further test of the observed complication rate against
NTCPprotons may revealmodel deﬁciencies and possibly trigger
Figure 3 Model-based selection validation of protons. Based on theΔNTCP-criteria, patients are either selected for photons
or protons. After treatmentwith protons, the observed complication rate is compared to the expected averageNTCP for the
entire cohort treated with photons. The null hypothesis (ie, no beneﬁt from protons) is rejected if the observed
complication rate is signiﬁcantly lower than the average NTCP for photons. (Color version of ﬁgure is available online.)
Clinical trial strategies 83model updates. Like the design of an RCT, a power analysis
should be performed before the study to calculate the number
of required patients.Rapid Learning Health Care
For the model-based approach, it is important to include all
patients in a similar data registration program, in which acute
and late toxicity preferably in combination with patient-
reported outcome measures are prospectively collected at
predeﬁned time points, within the framework of a so-called
rapid learning health care (RLHC) system16,17 (Fig. 4). This
allows for evaluation of the effect of protons on the primary
endpoint (eg, rate of a given late toxicity), but also on a wide
spectrum of secondary endpoints (eg, rates of acute and other
late toxicities or patient-reported outcome measures) either
patient-reported or physician-scored at different time points
and can be extended to cohort randomized clinical trials.16,17
The backbone of the RLHC system is prospective data
registration. The data obtained from these registries can be
used for the development of multivariable NTCP-models and
simultaneous external validation of these models when per-
formed in a multicenter setting. The dose-volume parameters
of these models can be used for model-based plan opti-
mization for protons and photons18,19 and for producing
ΔNTCP-proﬁles to select patients for either protons or
photons. All patients are then again subsequently entered in
the same prospective data registration program, whichallows for model-based validation when patients are treated
with protons. These prospectively collected data can also be
used to update NTCP-models when needed, for example,
by using the closed testing procedure as proposed by
Vergouwe et al.20 The closed testing procedure can be
used to decide on the extensiveness of the updating varying
from using the original model, through recalibration-in-
the-large (ie, re-estimation of the model intercept) and
recalibration (ie, re-estimation of the slope and intercept) to
the full model revision (ie, re-estimation of all coefﬁcients).
It is important to keep the possibility of updating NTCP-
models open as some authors found that NTCP-models
depend on radiation technology.21-23 In fact, the RLHC
system allows for a continuous improvement of radio-
therapy treatment planning and as such will continuously
improve outcome of radiotherapy in terms of radiation-
induced toxicity.Randomized Controlled Trials
There may be reasons to prefer an RCT over the model-based
approach for the validation of the added value of protons over
photons even when the primary aim is to reduce the risk of
radiation-induced side effects. RCTs could be considered in
case of a complete lack of proper NTCP-models; in case health
care authorities demand results of RCTs before reimbursement

























Figure 4 Rapid Learning Health Care system. All patients are subjected to prospective registration program. Data from this
registry are used for development and validation of multivariable NTCP-models. The dose-volume metrics in the NTCP-
models are used to optimize treatment planning and to produce theΔNTCP-proﬁle to select patients for either protons or
photons. Phase I, II, and III studies can be part of the RLHC system. (Color version of ﬁgure is available online.)
J.A. Langendijk et al.84decreased tumor control probability (TCP) or increased
toxicity other than the primary endpoint when protons are
applied, for example, increased dermatological toxicity owing
to higher entry dose levels with protons24 or increased central
nervous system toxicity owing to range uncertainties or higher
relative biological effectiveness.25 Like what has been men-
tioned in the previous paragraphs, in case of conducting RCTs
comparing protons with photons, improved outcome with
protons in terms of less toxicity can only be expected when the
dose to normal tissues is lower (Δdose) and if Δdose is
expected to translate into a reduction of NTCP (ΔNTCP).5
Recently, Widder et al pointed out that even in the case of an
RCT, population enrichment (ie, including patients only if a
certain level ofΔNTCP can be expected) is required, preferably
based on ΔNTCP-proﬁles if available, or, alternatively, at least
based on ΔDose-proﬁles or other biomarkers. Large and
highly powered nonenriched RCTs may yield positive results,
even when a large proportion of included cases will not have
any beneﬁt based on the absence or clinically irrelevantΔdose-
orΔNTCP-proﬁles.5 The consequence of such a “positive” trial
could be that when translated into routine clinical practice, too
many patients that will not beneﬁt from protons will remain
eligible, simply because they meet the nonenriched eligibility
criteria of the patients included in the trial. Conversely, owing
to dilution of any effect by inclusion of an even larger
proportion of patients who predictably will not beneﬁt, a
“negative” RCT might thus prohibit treating patients withprotons, even the ones with very favorable ΔNTCP-proﬁles
that are likely to beneﬁt from protons.5
Another problem with RCTs is that major differences exist
among proton therapy centers as illustrated by studies on
proton therapy clinical trial credentialing.26 Similar differences
have been found for IMRT.27,28 Heterogeneity among centers
may result from many factors, such as differences in proton
therapy delivery equipment, education and training skills,
treatment planning systems, treatment planning techniques,
center speciﬁc workﬂows, ﬁxation techniques, motion miti-
gation strategies, and machine and patient-speciﬁc quality
assurance procedures. In this regard, it is difﬁcult to compare a
new heterogeneous technique with IMRT considered as the
reference standard, although there is no standard IMRT. This
problembecomes increasingly importantwhen results of RCTs
are translated into routine clinical practice.
Previous studies showed that the quality of radiation treat-
ment planning and delivery varies widely among institutions
and are highly dependent on patient volume.29,30 Peters et al30
reported on the results of the quality assurance program of an
RCT comparing chemoradiation to chemoradiation with
tirapazamine, showing that treatment plans not compliant
with the research protocol were associated with signiﬁcantly
worse local control and overall survival rates. Major protocol
deﬁciencies were predominantly associated with lower num-
bers of patients enrolled in the study, with deﬁciencies being
less common with increasing institutional patient volume.
Clinical trial strategies 85Similar results were found in the RTOG 0617 lung cancer trial
in which patients with locally advanced non-small cell lung
cancer were randomly assigned to receive standard vs escalated
target dose; treatment at institutions with higher clinical trial
accrual volumes was associated with better progression-free
and overall survival rates.29 Patients treated in low volume
centers had higher esophageal and heart dose, had more grade
5 events andmore termination of radiotherapy owing to severe
toxicity.
These results highlight the importance of optimal dose
distributions and the need for meticulous quality assurance
programs, especially given the potential heterogeneity among
proton therapy centers and the possible clinical consequences
of these differences on clinical outcome, in terms of efﬁcacy as
well as potentially fatal toxicity.
These quality variability issues raise serious questions
regarding the generalizability of results obtained from RCTs
to routine clinical practice. As the success of treatment and the
added value of protons compared to photons depend to a great
extent on the performance of individual centers, a positive RCT
obtained in a controlled clinical research environment does not
a priori improve clinical outcome for individual patients when
treated with protons in centers that have not been subjected to
similar quality assurance programs. Consequently, even after a
successful positive RCT, translation of results from RCTs into
routine clinical practice still requires multicenter quality
assurance programs, especially for centers that are less expe-
rienced with treating eligible patients with the technique
investigated. This problem can be addressed in part by
integrating quality assurance programs in the RLHC systems.Cohort Multiple Randomized
Controlled Trials
Recently, Relton et al31 presented another study design: the so-
called cohortmultiple RCTs (cmRCT). In this design, a speciﬁc
and large cohort of patients is deﬁned (eg, patients treatedwith
radiotherapy for lung cancer) and followed prospectively, for
example, within the framework of an RLHC, with assessment
of toxicity and patient-reported outcome measures at ﬁxed
time points.16 This cohort can then be used to test several
interventions at the same time. One of the differences with the
classical RCT is that patients consent to participate in the
prospective data registry and to the possibility to be randomly
offered a new intervention (eg, protons instead of photons)
when they meet predeﬁned eligibility criteria, whereas the
patients in the control group are not approached for further
consent. Eventually, the results obtained in the patient cohort
treated with the new irradiation technology (eg, protons) can
be compared to those obtained in the complete patient cohort
treated with the standard radiation technology (eg, photons).
The main advantages of cmRCT are: improved accrual rates,37
the possibility to perform multiple trials within the same
cohort, reduced costs for the control arm and the possibility to
compare the results to real life practice. This design is
particularly useful in case of expensive interventions like
protons and high patients’ preference to accept the newintervention.16 Like what has been mentioned for the classical
RCT, additional study requirements like population enrich-
ment using model-based selection and advanced quality
assurance programs are essential here as well.Discussion and Conclusion
Different evidence-based clinical trial strategies are available,
which can also be applied to investigate whether the use of
protons over photons is justiﬁed. The choice of trial design
depends on several factors, such as the primary study objective
(efﬁcacy vs prevention), the availability of high quality multi-
variable NTCP-models, ﬁnancial resources and national reim-
bursement policies. When investigating the added value of
protons over photons regarding improvement of local control,
RCTs are still the reference standard. When prevention of side
effects is the main objective to apply proton therapy, both
model-based validation and RCTs can be used, which both
have their advantages and disadvantages. Combining both
methodologies or with cmRCTs within the framework of
RLHC systems is most likely to provide the most comple-
mentary evidence-based environment to introduce and vali-
date new radiation modalities like proton therapy.
There is growing awareness in the radiotherapy community
that evidence-based selection of patients for new techniques
like protons is an unmet need. Some authors reported on other
selection methods for proton therapy, aiming at prediction of
Δdose, like geometric knowledge based methods in base of
skull tumors and head and neck cancer.31-34 These methods
may certainly be helpful in supporting radiation oncologists
working in centers where protons are not available to decide,
whether to refer patients to a proton therapy center, butmay be
less valuable in the ﬁnal decision to treat patients with protons
or photons given the earlier mentioned heterogeneity between
proton therapy centers. The approach espoused by Lühr et al35
uses a web-based software tool to support nonproton therapy
centers to determine the optimal radiation modality based on
patient-speciﬁc features.
In addition to selection of patients for proton therapy,
model-based selection may become a valuable tool for other
radiotherapy applications as well, especially as the availability
of proton therapy is expected to remain limited for the next few
years. In cases with low tumor control probabilities and
unfavorable NTCP-proﬁles, altered fractionation like hyper-
fractionation could be considered to increase the therapeutic
ratio by increasing local control without enhancing radiation-
induced side effects.36
Another development is to extendmodel-based selection by
considering not only ΔNTCP but the possible effects on TCP
as well, such as in the case of selection of breast cancer patients
for proton therapy.37 It should be noted that the model-based
approach as described here assumes that the target dose
remains biologically equivalent and that TCP is not affected.
To assess the possible effect on TCP, the Department of
Radiation Oncology of the University Medical Center Gronin-
gen is now implementing a special program for head and neck
cancer radiotherapy integrated in the RLHC system: the
J.A. Langendijk et al.86QUality AssuraNce TUMor (QUANTUM) program, consisting
of 3 major components: (1) A comprehensive quality assur-
ance program for the quality of delineation of target volumes.
(2) Automated monitoring of the cumulative target dose-
volume parameters during the course of treatment based on
repeated CT-scans and dose recalculations and (3) Model-
based continuous monitoring of TCP.
At present, one of the problems for the model-based
approach is that information on NTCP-models derived from
cohorts treated with protons is very limited.38 As NTCP-
models may depend on radiotherapy technique, it is not
unlikely that NTCP-models for proton treated patients are
different than the NTCP-models based on IMRT treated
patients. From a methodological point of view, this is not
really a major problem because for bothmodel-based selection
and model-based validation, different models for photons and
protons can be used simultaneously. The challenge here,
however, is to detect possible deviations from the original
NTCP-models and the need for model adjustment as soon as
possible. In principle, the RLHC system is a powerful tool to
detect the need for model adjustment and can be used to
continuously evaluate the need for updating NTCP-models
using the previously described closed testing procedure.
In conclusion, we have described 3 evidence-based
approaches to clinically validate the added value of protons:
(1) the model-based approach in which clinical implementa-
tion and continuous validation are integrated, (2) the classical
RCT approach, and (3) cmRCT. Combining these approaches
in RLHC systems is expected to yield the most efﬁcient and
scientiﬁcally sound way to continuously improve patient
selection and the therapeutic window, eventually leading to
more cancer survivors with better quality of life.References
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